

The Chemistry Behind Cannabis



Cannabinoids are chemical compounds that act directly and indirectly on cannabinoid receptors in the body. Medical cannabinoids are cannabinoids that recent research indicates have beneficial health effects.¹

BENEFIT/EFFECT **CANNABINOID** THC /THCA Psychotropic, pain reduction, antiinflammatory, anti-microbial. **Tetrahydrocannabinol** CBD / CBDA Relieves symptoms of anxiety, depression, seizures, inflammation, nausea, Acts as a Cannabidiol sedative, sleep aid, and muscle relaxant. CBC / CBCA Anti-inflammatory, pain reduction, treats acid reflux, anxiety and depression. Cannabichromene Pain reduction, muscle relaxant, anti-CBG / CBGA erythema, aids in digestion and stomach Cannabigerol function. **CBN / CBNA** Mild psychotropic, may stimulate bone growth, anesthetic, anti-convulsive, Cannahinol analgesic, antianxiety. Anti-obesity, aids memory, has calming THCV / THCVA effect, antibacterial, antiviral, boosts **Tetrahydocannabivarin** immune system. **CBDV / CBDVA** Anti-inflammatory, analgesic, protects cells and the lining of the digestive tract. Cannabidivarin

Sources: EQM Indexes, Cannabis.net

Amplify Seymour Cannabis ETF (CNBS)

CNBS is an ETF investing in the fast-developing global cannabis industry. The Fund is managed by Tim Seymour, a recognized voice and experienced investor in the cannabis space. We believe there is an opportunity to invest in companies engaged in businesses related to the cannabis industry.

¹https://phytatech.com/Science-Chemistry.php

Carefully consider the Fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in Amplify Funds statutory and summary prospectus, which may be obtained above or by calling 855-267-3837, or by visiting AmplifyETFs.com. Read the prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV, and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

The Fund is subject to management risk because it is an actively managed. Companies involved in the cannabis industry face competition, may have limited access to the services of banks, may have substantial burdens on company resources due to litigation, complaints or enforcement actions, and are heavily dependent on receiving necessary permits and authorizations to engage in medical cannabis research or to otherwise cultivate, possess or distribute cannabis. The possession and use of cannabis, even for medical purposes, is illegal under federal and certain states' laws, which may negatively impact the value of the Fund's investments. Securities issued by non-U.S. companies present risks beyond those of securities of U.S. issuers.

Many of the companies in which the Fund will invest are engaged in other lines of business unrelated to cannabis and these lines of business could adversely affect their operating results. Cannabis is a Schedule I controlled substance under the Controlled Substances Act ("CSA"), meaning that it has a high potential for abuse, has no currently "accepted medical use" in the U.S., lacks accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the U.S. Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments, and their securities may

be less liquid and may experience greater price volatility than larger, more established companies as a result of several factors, including limited trading volumes, products or financial resources, management inexperience and less publicly available information. The Fund is non-diversified, which can cause greater share price fluctuation.

Amplify Investments LLC is the Investment Adviser to the Fund, and Penserra Capital Management, LLC serves as the Investment Sub-Adviser.

QUESTIONS? Visit AmplifyETFs.com/CNBS

ONLINE: AmplifyETFs.com
EMAIL: info@AmplifyETFs.com

PHONE: 855-267-3837 | (855-AMP-ETFS)

